Evidence review
BPC-157 for GLP-1 Gut Damage
What this covers
GLP-1 agonists like semaglutide and tirzepatide cause gastric emptying delay in 30-40% of users. Nausea, vomiting, and diarrhea are common. Some patients develop gastroparesis-like symptoms.
What BPC-157 does
BPC-157 accelerates gastric emptying in rodent models. It protects gastric mucosa from NSAID and alcohol damage. It modulates nitric oxide signaling in the gut wall.
Evidence grade
- BPC-157 gastric emptying: rodent only, moderate quality
- BPC-157 mucosal protection: rodent + limited human case reports, moderate quality
- GLP-1 gut damage mechanism: clinical trial data, high quality
Practical note
No human trial has tested BPC-157 in GLP-1 users. The mechanistic rationale is strong but unproven clinically.
Ask this article · 2 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.
For my medical situation, what can you answer from your catalogue about BPC-157 for GLP-1 Gut Damage — and what would you need me to tell you first?
ask bpc-157-glp1-gut-damage condition gaps · paste includes §SELF
What good and bad outcomes are documented for BPC-157 for GLP-1 Gut Damage (studies vs anecdotes)?
ask bpc-157-glp1-gut-damage good bad experiences · paste includes §SELF